The Rare Disease Drug That Got Pulled Over for a Heart Check

The company hasn't disclosed exactly what the EKG changes looked like. No specific arrhythmia names. No QT prolongation numbers. Just the vague phrase "reversible cardiac observations," which is the corporate equivalent of saying "we found something and we'd rather not get into it right now."

The Unusual Silver Lining

Most clinical holds are purely bad news. This one comes with a twist.

Because the trials were already underway before the pause, Aardvark has actual Phase 3 data sitting in sealed envelopes, so to speak. The company enrolled 68 patients in its HERO trial and 19 in an open-label extension study before everything stopped. Now it plans to crack open that data and analyze it.

This is genuinely unusual. Phase 3 trials are typically unblinded only when they're done (or when a safety board forces the issue). Aardvark is choosing to peek at the cards early because it has no other move. If the data show strong efficacy at the therapeutic dose and a clean cardiac safety profile at that dose, the company can walk into the FDA's office with a compelling argument: the heart problems only happen at doses way above what patients actually take.

If the data don't cooperate, well, that's a different conversation entirely.

Why This Matters for a Community With Almost No Options

PWS is one of those diseases that makes you realize how lucky most people are to take "feeling full" for granted. Patients deal with constant, overwhelming hunger that requires 24/7 food supervision. Families literally lock their kitchens. The mortality rate among diagnosed PWS patients is roughly three times higher than the general population, driven by obesity-related complications like respiratory failure, diabetes, and heart disease.

For decades, there was nothing specifically approved to treat the hunger itself. Growth hormone therapy helps with body composition but doesn't touch the appetite. Behavioral interventions help, but they're exhausting for caregivers who can never let their guard down.

That changed in March 2025, when Soleno Therapeutics got FDA approval for VYKAT XR (diazoxide choline), the first drug specifically approved for hyperphagia in PWS for patients age four and older. It was a landmark moment, but it also means the competitive bar just got higher for everyone else.

ARD-101 was the most advanced challenger in the pipeline. If it survives this hold, it could offer patients a second option with a completely different mechanism. If it doesn't, the field gets noticeably thinner.

The Money Clock Is Ticking (But Not That Fast)

Aardvark went public in February 2025, raising about $94 million in its IPO on the Nasdaq. The company reported roughly $91.2 million in cash as of its latest disclosure, with a runway stretching into mid-2027. So this isn't a company that's going to run out of money next quarter.

That's important context. Some biotechs hit a clinical hold and immediately face an existential cash crisis. Aardvark has breathing room to negotiate with the FDA, run additional analyses, and potentially design new cardiac studies if needed. The question isn't whether they can afford to fight; it's whether the data give them something worth fighting for.

What Comes Next

The unblinded data will tell us a lot. There are basically three scenarios:

Best case: ARD-101 shows meaningful hunger reduction at the therapeutic dose with no cardiac red flags in PWS patients. Aardvark uses this to argue for a modified protocol (maybe lower dose caps, stricter cardiac monitoring) and gets the hold lifted. The drug lives to fight another day.

Middle ground: Efficacy looks promising but the cardiac picture is murky. The FDA demands additional dedicated heart studies before allowing the program to restart. This adds a year or more to the timeline and likely requires fresh capital.

Worst case: The data reveal cardiac signals even at the intended dose, or the efficacy isn't strong enough to justify the risk. The program gets shelved, and Aardvark pivots to ARD-201 (its Phase 2 obesity candidate, a fixed-dose combination of ARD-101 plus a DPP-4 inhibitor) as a backup plan.

For the roughly 10,000 to 20,000 Americans living with PWS, each of these scenarios carries real weight. Many of these patients and families were counting on more options beyond a single approved drug. The next few months will determine whether ARD-101 becomes one of those options, or joins the growing list of promising PWS therapies that couldn't make it across the finish line.

Aardvark named itself after the first animal in the dictionary. Right now, it's fighting to make sure its drug doesn't end up being the first one scratched from the race.